[This corrects the article DOI: 10.18632/oncotarget.3214.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771454 | PMC |
| http://dx.doi.org/10.18632/oncotarget.27216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Publisher Correction: Specific 3-O-sulfated heparan sulfate domains regulate salivary gland basement membrane metabolism and epithelial differentiation.
Nat Commun
October 2024
Matrix and Morphogenesis Section, National Institute of Dental and Craniofacial Research, NIH, DHHS, Bethesda, MD, USA.
Chondroitin/dermatan sulphate proteoglycan, desmosealin, showing affinity to desmosomes.
Int J Cosmet Sci
August 2024
Tissue Biology and Therapeutic Engineering Laboratory (LBTI), UMR 5305 CNRS and Lyon1 University, Lyon, France.
Objective: Desmosomes are the most prominent interkeratinocyte junctions. The correct barrier function of stratified epithelia such as epidermis depends on their expression. During epidermal differentiation, the molecular composition of desmosomes evolves and so do their physical and chemical properties.
View Article and Find Full Text PDFAAV gene replacement therapy for treating MPS IIIC: Facilitating bystander effects via EV-mRNA cargo.
J Extracell Vesicles
July 2024
Gene Therapy Center, Chapel Hill, USA.
MPS IIIC is a lysosomal storage disease caused by mutations in heparan-α-glucosaminide N-acetyltransferase (HGSNAT), for which no treatment is available. Because HGSNAT is a trans-lysosomal-membrane protein, gene therapy for MPS IIIC needs to transduce as many cells as possible for maximal benefits. All cells continuously release extracellular vesicles (EVs) and communicate by exchanging biomolecules via EV trafficking.
View Article and Find Full Text PDFDesign and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy.
Mol Ther Methods Clin Dev
June 2024
Stem Cell & Neurotherapies Group, University of Manchester, Manchester, UK.
Hematopoietic stem cell gene therapy (HSCGT) is a promising therapeutic strategy for the treatment of neurodegenerative, metabolic disorders. The approach involves the introduction of a missing gene into patients' own stem cells via lentiviral-mediated transduction (TD). Once transplanted back into a fully conditioned patient, these genetically modified HSCs can repopulate the blood system and produce the functional protein, previously absent or non-functional in the patient, which can then cross-correct other affected cells in somatic organs and the central nervous system.
View Article and Find Full Text PDFModeling interactions between Heparan sulfate and proteins based on the Heparan sulfate microarray analysis.
Glycobiology
May 2024
Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, 1044 Genetic Medicine Bldg., University of North Carolina, Chapel Hill, NC 27599, United States.
Heparan sulfate (HS), a sulfated polysaccharide abundant in the extracellular matrix, plays pivotal roles in various physiological and pathological processes by interacting with proteins. Investigating the binding selectivity of HS oligosaccharides to target proteins is essential, but the exhaustive inclusion of all possible oligosaccharides in microarray experiments is impractical. To address this challenge, we present a hybrid pipeline that integrates microarray and in silico techniques to design oligosaccharides with desired protein affinity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!